• Patient Prefer Adher · Jan 2023

    Perception and Experience of Dupilumab in Atopic Dermatitis: A Real-Life Study.

    • Léa Antoine, Eve Puzenat, Dragos Popescu, Romain Charollais, Flora Dresco, Anne-Sophie Dupond, Dominique Salard, Marie-Christine Drobacheff-Thiebaut, Anaïs Zanella, Anne Ducournau, Iréne Gallais-Serezal, and François Aubin.
    • Department of Dermatology, University Hospital, Besançon, France.
    • Patient Prefer Adher. 2023 Jan 1; 17: 228922932289-2293.

    PurposeThere are few data on the practical use of dupilumab by the patients and on the patients' experience with this treatment.ObjectiveThe objective of our study was to describe the experience and perception of dupilumab treatment in patients with atopic dermatitis (AD).Patients And MethodsWe conducted a multicenter retrospective observational study including adult patients with moderate to severe AD treated with dupilumab between January 2017 and December 2021. Clinical characteristics were collected and a questionnaire was sent to all patients. It consisted of different parts including the injection method and different numeric rating scales (NRS) evaluating the patient's satisfaction and the constraints related to the treatment.ResultsEighty-two patients were included and the information was available for 77 patients who responded to the questionnaire. Injection of dupilumab was performed by a nurse in 47% (n=36) of patients and 43% (n=33) were autonomous. Injections were performed by a family member for 7 patients or by the general practitioner (1 patient). A wearing-off of the beneficial effect of dupilumab was reported by 47% of patients leading to shorten the dosing interval. In contrast, dose spacing was reported by 9 patients (11%). After a mean follow-up time of 29.7 ± 10.7 months (median: 27 months), drug survival was 72%. From the patients' perspective, the mean patient's satisfaction NRS score was 7.5 ± 1.8, and the constraints related to the treatment were scored at 3.1 ± 2.1 on NRS.ConclusionAlthough AD treatments may contribute to the burden of the disease, dupilumab was associated with a lower burden score, likely reflecting both treatment efficacy and easy of use and patient satisfaction.© 2023 Antoine et al.

      Pubmed     Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…